DE69824730T2 - Zusammensetzungen, kits und verfahren zur hemmung von zerebralen neurovasculären störungen und muskulärem kopfschmerzen - Google Patents
Zusammensetzungen, kits und verfahren zur hemmung von zerebralen neurovasculären störungen und muskulärem kopfschmerzen Download PDFInfo
- Publication number
- DE69824730T2 DE69824730T2 DE69824730T DE69824730T DE69824730T2 DE 69824730 T2 DE69824730 T2 DE 69824730T2 DE 69824730 T DE69824730 T DE 69824730T DE 69824730 T DE69824730 T DE 69824730T DE 69824730 T2 DE69824730 T2 DE 69824730T2
- Authority
- DE
- Germany
- Prior art keywords
- headache
- local anesthetic
- administration
- patient
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010019233 Headaches Diseases 0.000 title claims description 326
- 231100000869 headache Toxicity 0.000 title claims description 317
- 239000000203 mixture Substances 0.000 title claims description 135
- 230000003387 muscular Effects 0.000 title claims description 104
- 208000017376 neurovascular disease Diseases 0.000 title claims description 19
- 238000000034 method Methods 0.000 title description 145
- 230000002401 inhibitory effect Effects 0.000 title description 21
- 239000003589 local anesthetic agent Substances 0.000 claims description 313
- 229960001549 ropivacaine Drugs 0.000 claims description 141
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims description 137
- 206010027599 migraine Diseases 0.000 claims description 129
- 150000001875 compounds Chemical class 0.000 claims description 123
- 208000019695 Migraine disease Diseases 0.000 claims description 113
- 208000024891 symptom Diseases 0.000 claims description 95
- 238000011282 treatment Methods 0.000 claims description 78
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 64
- 230000001154 acute effect Effects 0.000 claims description 64
- 229960004194 lidocaine Drugs 0.000 claims description 63
- 229960005015 local anesthetics Drugs 0.000 claims description 59
- 230000002490 cerebral effect Effects 0.000 claims description 56
- -1 amylocain Chemical compound 0.000 claims description 55
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 52
- 229960003150 bupivacaine Drugs 0.000 claims description 52
- 239000003814 drug Substances 0.000 claims description 51
- 241000282414 Homo sapiens Species 0.000 claims description 45
- 239000013543 active substance Substances 0.000 claims description 42
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 42
- 229940079593 drug Drugs 0.000 claims description 40
- 208000009205 Tinnitus Diseases 0.000 claims description 34
- 231100000886 tinnitus Toxicity 0.000 claims description 32
- 230000000302 ischemic effect Effects 0.000 claims description 28
- 208000006561 Cluster Headache Diseases 0.000 claims description 27
- 210000003928 nasal cavity Anatomy 0.000 claims description 23
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 229960003920 cocaine Drugs 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 19
- 239000007787 solid Substances 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 18
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 15
- 208000001286 intracranial vasospasm Diseases 0.000 claims description 15
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims description 14
- 206010043269 Tension headache Diseases 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000000499 gel Substances 0.000 claims description 10
- 208000037048 Prodromal Symptoms Diseases 0.000 claims description 8
- 230000009471 action Effects 0.000 claims description 8
- 239000000374 eutectic mixture Substances 0.000 claims description 8
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 7
- 206010059109 Cerebral vasoconstriction Diseases 0.000 claims description 7
- 208000005392 Spasm Diseases 0.000 claims description 7
- 229960002409 mepivacaine Drugs 0.000 claims description 7
- 229960003976 etidocaine Drugs 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000006260 foam Substances 0.000 claims description 5
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 claims description 5
- 229960004288 levobupivacaine Drugs 0.000 claims description 5
- 229960000482 pethidine Drugs 0.000 claims description 5
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 4
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims description 4
- 229960005305 adenosine Drugs 0.000 claims description 4
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- NBFQYHKHPBMJJV-UHFFFAOYSA-N risocaine Chemical compound CCCOC(=O)C1=CC=C(N)C=C1 NBFQYHKHPBMJJV-UHFFFAOYSA-N 0.000 claims description 4
- 229960002372 tetracaine Drugs 0.000 claims description 4
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims description 4
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims description 3
- 229960001807 prilocaine Drugs 0.000 claims description 3
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 3
- HZGRVVUQEIBCMS-HTRCEHHLSA-N (1s,5r)-8-methyl-8-azabicyclo[3.2.1]oct-3-ene-4-carboxylic acid Chemical compound C1C=C(C(O)=O)[C@H]2CC[C@@H]1N2C HZGRVVUQEIBCMS-HTRCEHHLSA-N 0.000 claims description 2
- HGKAMARNFGKMLC-MOPGFXCFSA-N (2r)-2-[(4r)-2,2-diphenyl-1,3-dioxolan-4-yl]piperidine Chemical compound C([C@@H]1[C@H]2OC(OC2)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCN1 HGKAMARNFGKMLC-MOPGFXCFSA-N 0.000 claims description 2
- CAFOIGUDKPQBIO-BYIOMEFUSA-N (r)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-[6-(3-methylbutoxy)quinolin-4-yl]methanol Chemical compound C1=C(OCCC(C)C)C=C2C([C@@H](O)[C@@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 CAFOIGUDKPQBIO-BYIOMEFUSA-N 0.000 claims description 2
- ZLMQPGUWYWFPEG-UHFFFAOYSA-N 2-(diethylamino)ethyl 4-amino-2-butoxybenzoate Chemical compound CCCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC ZLMQPGUWYWFPEG-UHFFFAOYSA-N 0.000 claims description 2
- GHSCYMOJHVOGDJ-UHFFFAOYSA-N 2-(diethylamino)ethyl 4-amino-2-hydroxybenzoate Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1O GHSCYMOJHVOGDJ-UHFFFAOYSA-N 0.000 claims description 2
- PUYOAVGNCWPANW-UHFFFAOYSA-N 2-methylpropyl 4-aminobenzoate Chemical compound CC(C)COC(=O)C1=CC=C(N)C=C1 PUYOAVGNCWPANW-UHFFFAOYSA-N 0.000 claims description 2
- HQFWVSGBVLEQGA-UHFFFAOYSA-N 4-aminobenzoic acid 3-(dibutylamino)propyl ester Chemical compound CCCCN(CCCC)CCCOC(=O)C1=CC=C(N)C=C1 HQFWVSGBVLEQGA-UHFFFAOYSA-N 0.000 claims description 2
- 235000001258 Cinchona calisaya Nutrition 0.000 claims description 2
- PHMBVCPLDPDESM-YWIQKCBGSA-N Ecgonine Natural products C1[C@H](O)[C@@H](C(O)=O)[C@H]2CC[C@@H]1N2C PHMBVCPLDPDESM-YWIQKCBGSA-N 0.000 claims description 2
- VNQABZCSYCTZMS-UHFFFAOYSA-N Orthoform Chemical compound COC(=O)C1=CC=C(O)C(N)=C1 VNQABZCSYCTZMS-UHFFFAOYSA-N 0.000 claims description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
- YQKAVWCGQQXBGW-UHFFFAOYSA-N Piperocaine Chemical compound CC1CCCCN1CCCOC(=O)C1=CC=CC=C1 YQKAVWCGQQXBGW-UHFFFAOYSA-N 0.000 claims description 2
- 229920001363 Polidocanol Polymers 0.000 claims description 2
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 claims description 2
- CAJIGINSTLKQMM-UHFFFAOYSA-N Propoxycaine Chemical compound CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC CAJIGINSTLKQMM-UHFFFAOYSA-N 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- FVECELJHCSPHKY-UHFFFAOYSA-N Veratridine Natural products C1=C(OC)C(OC)=CC=C1C(=O)OC1C2(O)OC34CC5(O)C(CN6C(CCC(C)C6)C6(C)O)C6(O)C(O)CC5(O)C4CCC2C3(C)CC1 FVECELJHCSPHKY-UHFFFAOYSA-N 0.000 claims description 2
- RFPVXZWXDPIKSD-UHFFFAOYSA-N [2-(diethylamino)-4-methylpentyl] 4-aminobenzoate;methanesulfonic acid Chemical compound CS(O)(=O)=O.CCN(CC)C(CC(C)C)COC(=O)C1=CC=C(N)C=C1 RFPVXZWXDPIKSD-UHFFFAOYSA-N 0.000 claims description 2
- VPRGXNLHFBBDFS-UHFFFAOYSA-N [3-(diethylamino)-1-phenylpropyl] benzoate Chemical compound C=1C=CC=CC=1C(CCN(CC)CC)OC(=O)C1=CC=CC=C1 VPRGXNLHFBBDFS-UHFFFAOYSA-N 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- HPITVGRITATAFY-UHFFFAOYSA-N amolanone Chemical compound O=C1OC2=CC=CC=C2C1(CCN(CC)CC)C1=CC=CC=C1 HPITVGRITATAFY-UHFFFAOYSA-N 0.000 claims description 2
- 229950009452 amolanone Drugs 0.000 claims description 2
- 229960005274 benzocaine Drugs 0.000 claims description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims description 2
- CXYOBRKOFHQONJ-UHFFFAOYSA-N betoxycaine Chemical compound CCCCOC1=CC=C(C(=O)OCCOCCN(CC)CC)C=C1N CXYOBRKOFHQONJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003369 butacaine Drugs 0.000 claims description 2
- IUWVALYLNVXWKX-UHFFFAOYSA-N butamben Chemical compound CCCCOC(=O)C1=CC=C(N)C=C1 IUWVALYLNVXWKX-UHFFFAOYSA-N 0.000 claims description 2
- 229960000400 butamben Drugs 0.000 claims description 2
- WDICTQVBXKADBP-UHFFFAOYSA-N butethamine Chemical compound CC(C)CNCCOC(=O)C1=CC=C(N)C=C1 WDICTQVBXKADBP-UHFFFAOYSA-N 0.000 claims description 2
- 229950009376 butethamine Drugs 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 claims description 2
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 claims description 2
- 229960001747 cinchocaine Drugs 0.000 claims description 2
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 2
- 229960004741 cyclomethycaine Drugs 0.000 claims description 2
- YLRNESBGEGGQBK-UHFFFAOYSA-N cyclomethycaine Chemical compound CC1CCCCN1CCCOC(=O)C(C=C1)=CC=C1OC1CCCCC1 YLRNESBGEGGQBK-UHFFFAOYSA-N 0.000 claims description 2
- PHMBVCPLDPDESM-UHFFFAOYSA-N d-Pseudoekgonin Natural products C1C(O)C(C(O)=O)C2CCC1N2C PHMBVCPLDPDESM-UHFFFAOYSA-N 0.000 claims description 2
- OWQIUQKMMPDHQQ-UHFFFAOYSA-N dimethocaine Chemical compound CCN(CC)CC(C)(C)COC(=O)C1=CC=C(N)C=C1 OWQIUQKMMPDHQQ-UHFFFAOYSA-N 0.000 claims description 2
- 229950010160 dimethocaine Drugs 0.000 claims description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960000385 dyclonine Drugs 0.000 claims description 2
- PHMBVCPLDPDESM-FKSUSPILSA-N ecgonine Chemical compound C1[C@H](O)[C@H](C(O)=O)[C@H]2CC[C@@H]1N2C PHMBVCPLDPDESM-FKSUSPILSA-N 0.000 claims description 2
- 229960003750 ethyl chloride Drugs 0.000 claims description 2
- 229950008467 euprocin Drugs 0.000 claims description 2
- CVHGCWVMTZWGAY-UHFFFAOYSA-N fomocaine Chemical compound C=1C=C(COC=2C=CC=CC=2)C=CC=1CCCN1CCOCC1 CVHGCWVMTZWGAY-UHFFFAOYSA-N 0.000 claims description 2
- 229950003051 fomocaine Drugs 0.000 claims description 2
- 229950000998 hydroxyprocaine Drugs 0.000 claims description 2
- DHCUQNSUUYMFGX-UHFFFAOYSA-N hydroxytetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C(O)=C1 DHCUQNSUUYMFGX-UHFFFAOYSA-N 0.000 claims description 2
- 229950000638 hydroxytetracaine Drugs 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 229950003548 levoxadrol Drugs 0.000 claims description 2
- ZPUCINDJVBIVPJ-XGUBFFRZSA-N methyl (1s,3s,4s,5r)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-XGUBFFRZSA-N 0.000 claims description 2
- HKOURKRGAFKVFP-UHFFFAOYSA-N octacaine Chemical compound CCN(CC)C(C)CC(=O)NC1=CC=CC=C1 HKOURKRGAFKVFP-UHFFFAOYSA-N 0.000 claims description 2
- 229950009333 octacaine Drugs 0.000 claims description 2
- 229950006098 orthocaine Drugs 0.000 claims description 2
- 229960003502 oxybuprocaine Drugs 0.000 claims description 2
- CMHHMUWAYWTMGS-UHFFFAOYSA-N oxybuprocaine Chemical compound CCCCOC1=CC(C(=O)OCCN(CC)CC)=CC=C1N CMHHMUWAYWTMGS-UHFFFAOYSA-N 0.000 claims description 2
- QXDAEKSDNVPFJG-UHFFFAOYSA-N phenacaine Chemical compound C1=CC(OCC)=CC=C1N\C(C)=N\C1=CC=C(OCC)C=C1 QXDAEKSDNVPFJG-UHFFFAOYSA-N 0.000 claims description 2
- 229950007049 phenacaine Drugs 0.000 claims description 2
- 229960001045 piperocaine Drugs 0.000 claims description 2
- BMIJYAZXNZEMLI-UHFFFAOYSA-N piridocaine Chemical compound NC1=CC=CC=C1C(=O)OCCC1NCCCC1 BMIJYAZXNZEMLI-UHFFFAOYSA-N 0.000 claims description 2
- 229950001038 piridocaine Drugs 0.000 claims description 2
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 claims description 2
- 229960002226 polidocanol Drugs 0.000 claims description 2
- 229920000151 polyglycol Polymers 0.000 claims description 2
- 239000010695 polyglycol Substances 0.000 claims description 2
- 229960001896 pramocaine Drugs 0.000 claims description 2
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 claims description 2
- 229950008865 propanocaine Drugs 0.000 claims description 2
- 229960003981 proparacaine Drugs 0.000 claims description 2
- STHAHFPLLHRRRO-UHFFFAOYSA-N propipocaine Chemical compound C1=CC(OCCC)=CC=C1C(=O)CCN1CCCCC1 STHAHFPLLHRRRO-UHFFFAOYSA-N 0.000 claims description 2
- 229950011219 propipocaine Drugs 0.000 claims description 2
- 229950003255 propoxycaine Drugs 0.000 claims description 2
- 229960000948 quinine Drugs 0.000 claims description 2
- 229950003447 risocaine Drugs 0.000 claims description 2
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 claims description 2
- TYWUGCGYWNSRPS-UHFFFAOYSA-N sameridine Chemical compound C1CN(CCCCCC)CCC1(C(=O)N(C)CC)C1=CC=CC=C1 TYWUGCGYWNSRPS-UHFFFAOYSA-N 0.000 claims description 2
- 229950000028 sameridine Drugs 0.000 claims description 2
- UDKICLZCJWQTLS-UHFFFAOYSA-N tolycaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C(=O)OC UDKICLZCJWQTLS-UHFFFAOYSA-N 0.000 claims description 2
- 229950006609 tolycaine Drugs 0.000 claims description 2
- GOZBHBFUQHMKQB-UHFFFAOYSA-N trimecaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=C(C)C=C1C GOZBHBFUQHMKQB-UHFFFAOYSA-N 0.000 claims description 2
- 229950002569 trimecaine Drugs 0.000 claims description 2
- 229940045136 urea Drugs 0.000 claims description 2
- FVECELJHCSPHKY-JLSHOZRYSA-N veratridine Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)O[C@@H]1[C@@]2(O)O[C@]34C[C@@]5(O)[C@H](CN6[C@@H](CC[C@H](C)C6)[C@@]6(C)O)[C@]6(O)[C@@H](O)C[C@@]5(O)[C@@H]4CC[C@H]2[C@]3(C)CC1 FVECELJHCSPHKY-JLSHOZRYSA-N 0.000 claims description 2
- HLDCSYXMVXILQC-UHFFFAOYSA-N xenysalate Chemical compound CCN(CC)CCOC(=O)C1=CC=CC(C=2C=CC=CC=2)=C1O HLDCSYXMVXILQC-UHFFFAOYSA-N 0.000 claims description 2
- 229960003434 xenysalate Drugs 0.000 claims description 2
- KYBJXENQEZJILU-UHFFFAOYSA-N zolamine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=NC=CS1 KYBJXENQEZJILU-UHFFFAOYSA-N 0.000 claims description 2
- 229950006211 zolamine Drugs 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims 3
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- BZRYYBWNOUALTQ-UHFFFAOYSA-N 2-[2-(6,6-dimethyl-4-bicyclo[3.1.1]hept-3-enyl)ethoxy]-n,n-diethylethanamine Chemical compound CCN(CC)CCOCCC1=CCC2C(C)(C)C1C2 BZRYYBWNOUALTQ-UHFFFAOYSA-N 0.000 claims 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 claims 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims 1
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 claims 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims 1
- NMPOSNRHZIWLLL-XUWVNRHRSA-N Cocaethylene Chemical group O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OCC)C(=O)C1=CC=CC=C1 NMPOSNRHZIWLLL-XUWVNRHRSA-N 0.000 claims 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 claims 1
- 229960003190 adenosine monophosphate Drugs 0.000 claims 1
- 229960002227 clindamycin Drugs 0.000 claims 1
- 229960005287 lincomycin Drugs 0.000 claims 1
- WRMRXPASUROZGT-UHFFFAOYSA-N monoethylglycinexylidide Chemical compound CCNCC(=O)NC1=C(C)C=CC=C1C WRMRXPASUROZGT-UHFFFAOYSA-N 0.000 claims 1
- 229960001860 salicylate Drugs 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 description 98
- 230000036407 pain Effects 0.000 description 98
- 239000003795 chemical substances by application Substances 0.000 description 57
- 210000001519 tissue Anatomy 0.000 description 52
- 230000000694 effects Effects 0.000 description 50
- 210000005036 nerve Anatomy 0.000 description 49
- 230000002085 persistent effect Effects 0.000 description 45
- 238000009472 formulation Methods 0.000 description 44
- 206010002091 Anaesthesia Diseases 0.000 description 43
- 230000037005 anaesthesia Effects 0.000 description 43
- 210000004204 blood vessel Anatomy 0.000 description 42
- 210000002850 nasal mucosa Anatomy 0.000 description 40
- 230000003444 anaesthetic effect Effects 0.000 description 38
- 230000005764 inhibitory process Effects 0.000 description 32
- 230000001537 neural effect Effects 0.000 description 32
- 230000009885 systemic effect Effects 0.000 description 26
- 239000000243 solution Substances 0.000 description 25
- 230000009467 reduction Effects 0.000 description 24
- 239000008194 pharmaceutical composition Substances 0.000 description 23
- 239000007921 spray Substances 0.000 description 22
- 229920000742 Cotton Polymers 0.000 description 21
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 21
- 230000002792 vascular Effects 0.000 description 20
- 229960003708 sumatriptan Drugs 0.000 description 19
- 208000035475 disorder Diseases 0.000 description 18
- 238000013268 sustained release Methods 0.000 description 18
- 239000012730 sustained-release form Substances 0.000 description 18
- 208000003098 Ganglion Cysts Diseases 0.000 description 17
- 208000005400 Synovial Cyst Diseases 0.000 description 17
- 230000004118 muscle contraction Effects 0.000 description 17
- 238000012384 transportation and delivery Methods 0.000 description 17
- 239000000952 serotonin receptor agonist Substances 0.000 description 16
- 239000005526 vasoconstrictor agent Substances 0.000 description 16
- 210000003205 muscle Anatomy 0.000 description 15
- 230000000306 recurrent effect Effects 0.000 description 15
- 238000012385 systemic delivery Methods 0.000 description 14
- 238000009826 distribution Methods 0.000 description 13
- 210000000981 epithelium Anatomy 0.000 description 13
- 210000003128 head Anatomy 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 238000007917 intracranial administration Methods 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 238000005192 partition Methods 0.000 description 13
- 230000000638 stimulation Effects 0.000 description 13
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 210000003901 trigeminal nerve Anatomy 0.000 description 12
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 10
- 230000000202 analgesic effect Effects 0.000 description 10
- 230000006378 damage Effects 0.000 description 10
- 230000035790 physiological processes and functions Effects 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 230000000304 vasodilatating effect Effects 0.000 description 10
- 230000024883 vasodilation Effects 0.000 description 10
- 230000000007 visual effect Effects 0.000 description 10
- 206010028813 Nausea Diseases 0.000 description 9
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 9
- 206010047163 Vasospasm Diseases 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 208000028867 ischemia Diseases 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 239000007922 nasal spray Substances 0.000 description 9
- 229940097496 nasal spray Drugs 0.000 description 9
- 230000008693 nausea Effects 0.000 description 9
- 230000000926 neurological effect Effects 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- ULFRLSNUDGIQQP-UHFFFAOYSA-N rizatriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CN1C=NC=N1 ULFRLSNUDGIQQP-UHFFFAOYSA-N 0.000 description 9
- 230000000699 topical effect Effects 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 8
- 210000002027 skeletal muscle Anatomy 0.000 description 8
- 206010001497 Agitation Diseases 0.000 description 7
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 7
- 208000006011 Stroke Diseases 0.000 description 7
- 229960001138 acetylsalicylic acid Drugs 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000003292 diminished effect Effects 0.000 description 7
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 230000004807 localization Effects 0.000 description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 229960000425 rizatriptan Drugs 0.000 description 7
- 230000001953 sensory effect Effects 0.000 description 7
- 230000002459 sustained effect Effects 0.000 description 7
- ULSDMUVEXKOYBU-ZDUSSCGKSA-N zolmitriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1C[C@H]1COC(=O)N1 ULSDMUVEXKOYBU-ZDUSSCGKSA-N 0.000 description 7
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 6
- 229930182837 (R)-adrenaline Natural products 0.000 description 6
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 239000002876 beta blocker Substances 0.000 description 6
- 229940097320 beta blocking agent Drugs 0.000 description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
- 238000004891 communication Methods 0.000 description 6
- 230000008602 contraction Effects 0.000 description 6
- 229960005139 epinephrine Drugs 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 230000001771 impaired effect Effects 0.000 description 6
- 210000004914 menses Anatomy 0.000 description 6
- 239000002858 neurotransmitter agent Substances 0.000 description 6
- 210000001331 nose Anatomy 0.000 description 6
- 229960005489 paracetamol Drugs 0.000 description 6
- 230000001457 vasomotor Effects 0.000 description 6
- 206010010904 Convulsion Diseases 0.000 description 5
- 206010034960 Photophobia Diseases 0.000 description 5
- 206010047139 Vasoconstriction Diseases 0.000 description 5
- 239000002250 absorbent Substances 0.000 description 5
- 230000002745 absorbent Effects 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000003727 cerebral blood flow Effects 0.000 description 5
- 238000011260 co-administration Methods 0.000 description 5
- 239000006196 drop Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000004228 maxillary nerve Anatomy 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000003533 narcotic effect Effects 0.000 description 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 238000007910 systemic administration Methods 0.000 description 5
- 230000025033 vasoconstriction Effects 0.000 description 5
- 229960001360 zolmitriptan Drugs 0.000 description 5
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 4
- KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 4
- 208000007101 Muscle Cramp Diseases 0.000 description 4
- AWEZYKMQFAUBTD-UHFFFAOYSA-N Naratriptan hydrochloride Chemical compound [H+].[Cl-].C12=CC(CCS(=O)(=O)NC)=CC=C2NC=C1C1CCN(C)CC1 AWEZYKMQFAUBTD-UHFFFAOYSA-N 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 208000014604 Specific Language disease Diseases 0.000 description 4
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 201000007201 aphasia Diseases 0.000 description 4
- 230000002146 bilateral effect Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000036770 blood supply Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 210000004889 cervical nerve Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 229960001186 methysergide Drugs 0.000 description 4
- 210000001589 microsome Anatomy 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000001734 parasympathetic effect Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000008447 perception Effects 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 229960003712 propranolol Drugs 0.000 description 4
- 230000002787 reinforcement Effects 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 235000019615 sensations Nutrition 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 230000002889 sympathetic effect Effects 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 239000003204 tranquilizing agent Substances 0.000 description 4
- 230000002936 tranquilizing effect Effects 0.000 description 4
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 4
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 241001535291 Analges Species 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 description 3
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 206010028836 Neck pain Diseases 0.000 description 3
- 108090000189 Neuropeptides Proteins 0.000 description 3
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 3
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 3
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 210000003484 anatomy Anatomy 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 230000002051 biphasic effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- UZVHFVZFNXBMQJ-UHFFFAOYSA-N butalbital Chemical compound CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O UZVHFVZFNXBMQJ-UHFFFAOYSA-N 0.000 description 3
- 229960002546 butalbital Drugs 0.000 description 3
- GMTYREVWZXJPLF-AFHUBHILSA-N butorphanol D-tartrate Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 GMTYREVWZXJPLF-AFHUBHILSA-N 0.000 description 3
- 229960001590 butorphanol tartrate Drugs 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- 239000000480 calcium channel blocker Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229960005233 cineole Drugs 0.000 description 3
- 229960000265 cromoglicic acid Drugs 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- COVOMQKTVSVWBZ-CJCGOCGYSA-N deoxytetrodotoxin Chemical compound O1C(C2(O)CO)(O)OC3C(O)C1[C@@H]1CN=C(N)NC12C3O COVOMQKTVSVWBZ-CJCGOCGYSA-N 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229960004704 dihydroergotamine Drugs 0.000 description 3
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 3
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229960004943 ergotamine Drugs 0.000 description 3
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 3
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical group 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 230000005496 eutectics Effects 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 229960002870 gabapentin Drugs 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 229910001416 lithium ion Inorganic materials 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910001425 magnesium ion Inorganic materials 0.000 description 3
- 210000002161 motor neuron Anatomy 0.000 description 3
- 229960005254 naratriptan Drugs 0.000 description 3
- 210000004126 nerve fiber Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 230000008058 pain sensation Effects 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- RPQXVSUAYFXFJA-HGRQIUPRSA-N saxitoxin Chemical compound NC(=O)OC[C@@H]1N=C(N)N2CCC(O)(O)[C@@]22N=C(N)N[C@@H]12 RPQXVSUAYFXFJA-HGRQIUPRSA-N 0.000 description 3
- RPQXVSUAYFXFJA-UHFFFAOYSA-N saxitoxin hydrate Natural products NC(=O)OCC1N=C(N)N2CCC(O)(O)C22NC(N)=NC12 RPQXVSUAYFXFJA-UHFFFAOYSA-N 0.000 description 3
- 210000001044 sensory neuron Anatomy 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 229950010357 tetrodotoxin Drugs 0.000 description 3
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 3
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 3
- 229960001722 verapamil Drugs 0.000 description 3
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 206010013952 Dysphonia Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027603 Migraine headaches Diseases 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 208000028911 Temporomandibular Joint disease Diseases 0.000 description 2
- 206010043220 Temporomandibular joint syndrome Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 210000004960 anterior grey column Anatomy 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 229960001113 butorphanol Drugs 0.000 description 2
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 2
- 210000001326 carotid sinus Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 231100000895 deafness Toxicity 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000005670 electromagnetic radiation Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 210000001031 ethmoid bone Anatomy 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 210000000256 facial nerve Anatomy 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 210000001983 hard palate Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 229940090436 imitrex Drugs 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000036540 impulse transmission Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical class C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 description 2
- 210000001847 jaw Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940103177 maxalt Drugs 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 229940035363 muscle relaxants Drugs 0.000 description 2
- 210000004699 muscle spindle Anatomy 0.000 description 2
- 108091008709 muscle spindles Proteins 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- 239000004084 narcotic analgesic agent Substances 0.000 description 2
- 229940029571 naropin Drugs 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000002182 neurohumoral effect Effects 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 210000003300 oropharynx Anatomy 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 208000018316 severe headache Diseases 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 229940125725 tranquilizer Drugs 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 229940102566 valproate Drugs 0.000 description 2
- 230000002227 vasoactive effect Effects 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 230000002455 vasospastic effect Effects 0.000 description 2
- 229940003675 zomig Drugs 0.000 description 2
- KRCGPQRORHRZRC-SXWHKFHYSA-N (2s)-2-hydroxybutanedioic acid;(1s)-1-phenyl-2-pyridin-2-ylethanamine Chemical compound OC(=O)[C@@H](O)CC(O)=O.C([C@H](N)C=1C=CC=CC=1)C1=CC=CC=N1 KRCGPQRORHRZRC-SXWHKFHYSA-N 0.000 description 1
- VUCWMAJEUOWLEY-UHFFFAOYSA-N 1-$l^{1}-azanylpiperidine Chemical group [N]N1CCCCC1 VUCWMAJEUOWLEY-UHFFFAOYSA-N 0.000 description 1
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- JVKVEOKPRHZKNW-UHFFFAOYSA-N 2-hydroxybenzoic acid;hydrate Chemical compound O.OC(=O)C1=CC=CC=C1O JVKVEOKPRHZKNW-UHFFFAOYSA-N 0.000 description 1
- CBQKSVXEZOMTKP-UHFFFAOYSA-N 4-aminobutanoic acid;1h-1,2-benzodiazepine Chemical compound NCCCC(O)=O.N1N=CC=CC2=CC=CC=C12 CBQKSVXEZOMTKP-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- SQSPRWMERUQXNE-UHFFFAOYSA-N Guanylurea Chemical class NC(=N)NC(N)=O SQSPRWMERUQXNE-UHFFFAOYSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 206010054956 Phonophobia Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 206010039729 Scotoma Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000007156 Spondylarthritis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FDMBBCOBEAVDAO-UHFFFAOYSA-N Stovaine Chemical compound CN(C)CC(C)(CC)OC(=O)C1=CC=CC=C1 FDMBBCOBEAVDAO-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960000806 amylocaine Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003459 anti-dromic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000001042 autoregulative effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000008316 benzisoxazoles Chemical class 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 231100000060 cardiovascular toxicity Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 231100000153 central nervous system (CNS) toxicity Toxicity 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940028937 divalproex sodium Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 208000028329 epileptic seizure Diseases 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 206010019465 hemiparesis Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- XPXMKIXDFWLRAA-UHFFFAOYSA-N hydrazinide Chemical compound [NH-]N XPXMKIXDFWLRAA-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 150000005234 imidazo[1,2-a]pyridines Chemical class 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 210000000627 locus coeruleus Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- LJQWYEFHNLTPBZ-UHFFFAOYSA-N metabutoxycaine Chemical compound CCCCOC1=C(N)C=CC=C1C(=O)OCCN(CC)CC LJQWYEFHNLTPBZ-UHFFFAOYSA-N 0.000 description 1
- 229950004316 metabutoxycaine Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 210000000492 nasalseptum Anatomy 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 210000000118 neural pathway Anatomy 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000008587 neuronal excitability Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 229940052264 other local anesthetics in atc Drugs 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 239000012658 prophylactic medication Substances 0.000 description 1
- 230000009023 proprioceptive sensation Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 210000000598 pterygopalatine fossa Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000004189 reticular formation Anatomy 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 238000007391 self-medication Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000031893 sensory processing Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 210000002222 superior cervical ganglion Anatomy 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 210000003582 temporal bone Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000000427 trigeminal ganglion Anatomy 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 210000001944 turbinate Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002396 uvula Anatomy 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 230000008403 visual deficit Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US897192 | 1992-06-10 | ||
| US89719297A | 1997-07-21 | 1997-07-21 | |
| US7284598P | 1998-01-28 | 1998-01-28 | |
| US72845 | 1998-01-28 | ||
| US8455998P | 1998-05-06 | 1998-05-06 | |
| US84559 | 1998-05-06 | ||
| PCT/US1998/014870 WO1999003473A1 (en) | 1997-07-21 | 1998-07-17 | Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69824730D1 DE69824730D1 (de) | 2004-07-29 |
| DE69824730T2 true DE69824730T2 (de) | 2005-07-14 |
Family
ID=27372174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69824730T Expired - Lifetime DE69824730T2 (de) | 1997-07-21 | 1998-07-17 | Zusammensetzungen, kits und verfahren zur hemmung von zerebralen neurovasculären störungen und muskulärem kopfschmerzen |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP0999839B1 (https=) |
| JP (1) | JP4521117B2 (https=) |
| KR (1) | KR20010022041A (https=) |
| CN (1) | CN1267219A (https=) |
| AR (1) | AR013240A1 (https=) |
| AT (1) | ATE269702T1 (https=) |
| AU (1) | AU8574398A (https=) |
| BR (1) | BR9810773A (https=) |
| CA (1) | CA2297097C (https=) |
| DE (1) | DE69824730T2 (https=) |
| EE (1) | EE200000050A (https=) |
| HU (1) | HUP0003953A3 (https=) |
| ID (1) | ID24903A (https=) |
| IL (2) | IL134087A0 (https=) |
| IS (1) | IS5349A (https=) |
| NO (1) | NO20000293L (https=) |
| PL (1) | PL338176A1 (https=) |
| SK (1) | SK187899A3 (https=) |
| TR (1) | TR200000149T2 (https=) |
| WO (1) | WO1999003473A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9704349D0 (en) * | 1997-03-03 | 1997-04-23 | Chiroscience Ltd | Levobupivacaine and its use |
| JP4632499B2 (ja) * | 1999-08-26 | 2011-02-16 | 武田薬品工業株式会社 | 鼻粘膜付着マトリックス |
| AU2100901A (en) * | 1999-12-15 | 2001-06-25 | Bruce H. Levin | Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation |
| GB9930083D0 (en) * | 1999-12-20 | 2000-02-09 | Glaxo Group Ltd | Medicaments |
| US7117033B2 (en) | 2000-05-08 | 2006-10-03 | Brainsgate, Ltd. | Stimulation for acute conditions |
| AU5662001A (en) | 2000-05-08 | 2001-11-20 | Brainsgate Ltd. | Method and apparatus for stimulating the sphenopalatine ganglion to modify properties of the bbb and cerebral blood flow |
| US7640062B2 (en) | 2000-05-08 | 2009-12-29 | Brainsgate Ltd. | Methods and systems for management of alzheimer's disease |
| US7146209B2 (en) | 2000-05-08 | 2006-12-05 | Brainsgate, Ltd. | Stimulation for treating eye pathologies |
| US6853858B2 (en) | 2000-05-08 | 2005-02-08 | Brainsgate, Ltd. | Administration of anti-inflammatory drugs into the central nervous system |
| WO2004043218A2 (en) | 2002-11-14 | 2004-05-27 | Brainsgate Ltd. | Surgical tools and techniques for stimulation |
| US7561919B2 (en) | 2002-11-14 | 2009-07-14 | Brainsgate Ltd. | SPG stimulation via the greater palatine canal |
| WO2005062829A2 (en) | 2003-12-19 | 2005-07-14 | Advanced Bionics Corporation | Skull-mounted electrical stimulation system and method for treating patients |
| US8010189B2 (en) | 2004-02-20 | 2011-08-30 | Brainsgate Ltd. | SPG stimulation for treating complications of subarachnoid hemorrhage |
| US9233245B2 (en) | 2004-02-20 | 2016-01-12 | Brainsgate Ltd. | SPG stimulation |
| US8055347B2 (en) | 2005-08-19 | 2011-11-08 | Brainsgate Ltd. | Stimulation for treating brain events and other conditions |
| US7592371B2 (en) | 2004-08-18 | 2009-09-22 | Medrx Co., Ltd. | External preparation |
| AU2009274137B2 (en) * | 2008-07-21 | 2013-10-31 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
| DE102008037682A1 (de) | 2008-08-14 | 2010-04-08 | Strackharn, Klaus, Dr.med. | Verwendung äquipotenter Dosierungen von Lokalanästetika oder Derivaten davon zur Therapie chronischer Schmerzen |
| US9889109B2 (en) | 2012-09-28 | 2018-02-13 | St. Renatus, Llc | Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines |
| CN103432378A (zh) * | 2013-08-15 | 2013-12-11 | 吕清华 | 一种治疗神经血管性头痛的中药 |
| US9675796B2 (en) | 2013-11-10 | 2017-06-13 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
| US10271907B2 (en) | 2015-05-13 | 2019-04-30 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
| CN113573705A (zh) * | 2018-12-19 | 2021-10-29 | 诺迪克控股公司 | 鼻内利多卡因的治疗组合物 |
| WO2020152212A1 (en) * | 2019-01-22 | 2020-07-30 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Local anesthetic for the treatment of neurological symptoms resulting from brain dysfunctions |
| GB2628149A (en) * | 2023-03-16 | 2024-09-18 | Lee Nathaniel Wurie | Nasal spray for performing sphenopalatine ganglion block |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9321061D0 (en) * | 1993-10-13 | 1993-12-01 | Chiroscience Ltd | Analgestic agent and its use |
| DE19524691A1 (de) * | 1995-07-06 | 1997-01-09 | Liedtke Pharmed Gmbh | Methode und Zusammensetzung einer topischen Therapie von Innenohr und Labyrinth-Symptomen |
| DE19526019A1 (de) * | 1995-07-17 | 1997-01-23 | Liedtke Pharmed Gmbh | Methode und Zusammensetzung einer topischen Therapie von Kopfschmerzen |
| BE1009851A3 (fr) * | 1996-01-11 | 1997-10-07 | Thiebauld Charles Marie | Composition pharmaceutique pour le traitement des cephalees et son utilisation. |
| GB2315673A (en) * | 1996-08-01 | 1998-02-11 | Merck & Co Inc | Treatment of migraine |
| US5891885A (en) * | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
| GB9704349D0 (en) * | 1997-03-03 | 1997-04-23 | Chiroscience Ltd | Levobupivacaine and its use |
-
1998
- 1998-07-17 CN CN98808214A patent/CN1267219A/zh active Pending
- 1998-07-17 EP EP98936893A patent/EP0999839B1/en not_active Expired - Lifetime
- 1998-07-17 HU HU0003953A patent/HUP0003953A3/hu unknown
- 1998-07-17 IL IL13408798A patent/IL134087A0/xx active IP Right Grant
- 1998-07-17 AT AT98936893T patent/ATE269702T1/de not_active IP Right Cessation
- 1998-07-17 AU AU85743/98A patent/AU8574398A/en not_active Abandoned
- 1998-07-17 KR KR1020007000610A patent/KR20010022041A/ko not_active Withdrawn
- 1998-07-17 PL PL98338176A patent/PL338176A1/xx unknown
- 1998-07-17 DE DE69824730T patent/DE69824730T2/de not_active Expired - Lifetime
- 1998-07-17 TR TR2000/00149T patent/TR200000149T2/xx unknown
- 1998-07-17 JP JP2000502772A patent/JP4521117B2/ja not_active Expired - Fee Related
- 1998-07-17 WO PCT/US1998/014870 patent/WO1999003473A1/en not_active Ceased
- 1998-07-17 EE EEP200000050A patent/EE200000050A/xx unknown
- 1998-07-17 BR BR9810773-9A patent/BR9810773A/pt not_active IP Right Cessation
- 1998-07-17 CA CA002297097A patent/CA2297097C/en not_active Expired - Lifetime
- 1998-07-17 ID IDW20000123D patent/ID24903A/id unknown
- 1998-07-17 SK SK1878-99A patent/SK187899A3/sk unknown
- 1998-07-21 AR ARP980103565A patent/AR013240A1/es unknown
-
2000
- 2000-01-17 IL IL134087A patent/IL134087A/en not_active IP Right Cessation
- 2000-01-18 IS IS5349A patent/IS5349A/is unknown
- 2000-01-20 NO NO20000293A patent/NO20000293L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU8574398A (en) | 1999-02-10 |
| HUP0003953A3 (en) | 2002-02-28 |
| ID24903A (id) | 2000-08-31 |
| DE69824730D1 (de) | 2004-07-29 |
| BR9810773A (pt) | 2000-09-19 |
| CA2297097C (en) | 2009-04-07 |
| KR20010022041A (ko) | 2001-03-15 |
| PL338176A1 (en) | 2000-10-09 |
| NO20000293L (no) | 2000-03-20 |
| TR200000149T2 (tr) | 2000-05-22 |
| IL134087A (en) | 2006-10-31 |
| CA2297097A1 (en) | 1999-01-28 |
| EE200000050A (et) | 2000-10-16 |
| EP0999839B1 (en) | 2004-06-23 |
| EP0999839A1 (en) | 2000-05-17 |
| JP4521117B2 (ja) | 2010-08-11 |
| CN1267219A (zh) | 2000-09-20 |
| HUP0003953A1 (hu) | 2002-01-28 |
| NO20000293D0 (no) | 2000-01-20 |
| JP2001513483A (ja) | 2001-09-04 |
| SK187899A3 (en) | 2000-12-11 |
| IS5349A (is) | 2000-01-18 |
| WO1999003473A1 (en) | 1999-01-28 |
| ATE269702T1 (de) | 2004-07-15 |
| IL134087A0 (en) | 2001-04-30 |
| AR013240A1 (es) | 2000-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69824730T2 (de) | Zusammensetzungen, kits und verfahren zur hemmung von zerebralen neurovasculären störungen und muskulärem kopfschmerzen | |
| US6432986B2 (en) | Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches | |
| US6491940B1 (en) | Apparatus for administering composition for inhibiting cerebral neurovascular disorders and muscular headaches | |
| US9302096B2 (en) | Apparatus for treating cerebral neurovascular disorders including headaches by neural stimulation | |
| US20010004644A1 (en) | Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation | |
| US20220152394A1 (en) | Materials and methods for treating neuropathies and related disorders including those involving a keystone nerve | |
| Catterall et al. | Local anesthetics | |
| US20050281751A1 (en) | Directed intranasal administration of pharmaceutical agents | |
| DE602004003172T2 (de) | Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals | |
| DE69931042T2 (de) | Stoffe mit serotoninartiger wirkung zur behandlung der schlafapnoe | |
| US20160030408A1 (en) | Materials and methods for treating neuropathies and related disorders including those involving a keystone nerve | |
| MXPA96003633A (en) | Use of ketamine and device for the nasal and eye administration of ketamine for the management of pain and for detoxification | |
| EP2323645B1 (de) | Verwendung niedrig-dosierter lokalanästhetika oder derivate davon zur therapie chronischer schmerzen, insbesondere migräne | |
| WO2001043733A2 (en) | Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation | |
| DE60315258T2 (de) | Behandlung von nicht-schmerzhaften blasenstörungen mit modulatoren der alpha-2-delta-untereinheit des calciumkanals | |
| CA2885749A1 (en) | Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines | |
| CZ2000215A3 (cs) | Kompozice, kity a způsoby pro inhibici cerebrálních neurovaskuiárních poruch a svalové bolestí hlavy | |
| MXPA00000705A (en) | Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches | |
| Nguyen | Topical Anesthetics and Local and Regional Blocks | |
| DE102004040630A1 (de) | Kombinationstherapie mit Procain | |
| MXPA99008056A (en) | The use of levobupivacaine or ropivacaine in treating migraine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |